ABCB4 disease-causing variants S242R, S346I, T437I and T1077M significantly impair its function and display differential sensitivity to potentiators

The hepato-canalicular adenosine triphosphate (ATP)-binding cassette transporter ABCB4/MDR3 is responsible of the secretion of phosphatidylcholine (PC) into bile. Variations in ABCB4 gene induce a spectrum of cholestatic liver diseases, the most severe form is progressive familial intrahepatic cholestasis type 3 (PFIC3). The purpose of our study was to investigate the impact and potential rescue of four ABCB4 missense variants identified in patients, two of which (T437I and T1077M) affect homologous amino acids in the Walker A motifs in the two nucleotide-binding sites NBS2 and NBS1, respectively and the other two (S242R and S346I) affect residues of the transmembrane helices 4 and 6, respectively. The functional role of the four amino acids was assessed by analysis of three-dimensional (3D) structures and molecular dynamics (MD) simulations in a lipid bilayer. For functional validation, the mutants were reproduced in a plasmid encoding the human ABCB4 protein. The localization, the processing and the PC secretion activity of the mutants were studied after transfection in cell models. As the wild-type ABCB4, all four mutants expressed and trafficked efficiently to the canalicular membrane of HepG2 cells, but were dramatically impaired in PC secretion activity. This behavior can be explained by the critical positions of the amino acids in the NBSs and in a region participating in the substrate transport. The Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) potentiators ivacaftor and Small Binder of CFTR 219 (SBC219) significantly rescued the function defect of the mutants with differential sensitivity. Our results demonstrate the importance of the four mutated residues for ABCB4 function, which may explain the pathogenic phenotype. They provide an experimental evidence that targeted pharmacotherapy for genetic diseases caused by ABCB4 deficiency is likely to be mutation-specific.

Authors

Institutions

Publication Details

Journal
Scientific Reports
Published
2025-11-22
DOI
https://doi.org/10.1038/s41598-025-28407-6
Primary Topic
Drug Transport and Resistance Mechanisms
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

ABCB4 disease-causing variants S242R, S346I, T437I and T1077M significantly impair its function and display differential sensitivity to potentiators

Jean‐Luc Décout, Ahmad Elbahnsi, Claire Madry, Sara Lemoinne et al.
Scientific Reports
Drug Transport and Resistance Mechanisms
article

ABCB4 disease-causing variants S242R, S346I, T437I and T1077M significantly impair its function and display differential sensitivity to potentiators

Jean‐Luc Décout, Ahmad Elbahnsi, Claire Madry, Sara Lemoinne, Philippe Couvert, J. Delaunay, Tounsia Aït‐Slimane, Jérémie Gautheron, Sylvie Lagaye, Benjamin Boucherle, Nicolas Chignard, Isabelle Callebaut, Christophe Corpechot, Anne Stary
article en

Abstract

The hepato-canalicular adenosine triphosphate (ATP)-binding cassette transporter ABCB4/MDR3 is responsible of the secretion of phosphatidylcholine (PC) into bile. Variations in ABCB4 gene induce a spectrum of cholestatic liver diseases, the most severe form is progressive familial intrahepatic cholestasis type 3 (PFIC3). The purpose of our study was to investigate the impact and potential rescue of four ABCB4 missense variants identified in patients, two of which (T437I and T1077M) affect homologous amino acids in the Walker A motifs in the two nucleotide-binding sites NBS2 and NBS1, respectively and the other two (S242R and S346I) affect residues of the transmembrane helices 4 and 6, respectively. The functional role of the four amino acids was assessed by analysis of three-dimensional (3D) structures and molecular dynamics (MD) simulations in a lipid bilayer. For functional validation, the mutants were reproduced in a plasmid encoding the human ABCB4 protein. The localization, the processing and the PC secretion activity of the mutants were studied after transfection in cell models. As the wild-type ABCB4, all four mutants expressed and trafficked efficiently to the canalicular membrane of HepG2 cells, but were dramatically impaired in PC secretion activity. This behavior can be explained by the critical positions of the amino acids in the NBSs and in a region participating in the substrate transport. The Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) potentiators ivacaftor and Small Binder of CFTR 219 (SBC219) significantly rescued the function defect of the mutants with differential sensitivity. Our results demonstrate the importance of the four mutated residues for ABCB4 function, which may explain the pathogenic phenotype. They provide an experimental evidence that targeted pharmacotherapy for genetic diseases caused by ABCB4 deficiency is likely to be mutation-specific.

Scientific ReportsVol. 15(1)
Centre National de la Recherche Scientifique (FR), Inserm (FR), Université Paris Cité (FR), Sorbonne Université (FR), Hôpital Armand-Trousseau (FR), Sorbonne Paris Cité (FR), Laboratoire de Minéralogie & Cosmochimie du Muséum (FR), Assistance Publique – Hôpitaux de Paris (FR), Hôpital Saint-Antoine (FR), Centre de Recherche Saint-Antoine (FR), Institut de minéralogie, de physique des matériaux et de cosmochimie (FR), Maladies génétiques d’expression pédiatrique, Université Grenoble Alpes (FR)
Openalex Percentile: Top 51%
Drug Transport and Resistance Mechanisms
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.